Development and Use of Diagnostic Testing
Bryan Loy, MD, discusses how the FDA approval process for emerging diagnostic tests is becoming more rigorous and well defined. He notes that this guidance should be of help in theplanning stages of test development. Dr Loy explains that many of these tests are being developed in the laboratory industry rather than the pharmaceutical industry. He insists that innovation should not be stifled, and that it is in everyone’s interest to move tests quickly through the approval process to market while ensuring their validity.
Dr Loy is uncertain about how well providers really understand the development process, or in some cases, even the quality, the analytic validity, and the methodology of those tests. Therefore, adoption will be based on a variety of factors including price point, accessibility, decentralization, interpretability of the information, ease of doing business, and ability to return results fast enough to avoid delaying therapy.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Radiotherapy Raises Risk of Complications After Limb STS Surgery
September 16th 2025
- miRNA Profiling May Unlock SCLC Biomarkers
September 13th 2025
- Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move
September 11th 2025
- FDA Approves Selumetinib for Children With NF1 and Inoperable Tumors
September 10th 2025